Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Caribou Biosciences (CRBU) has issued an announcement.
Caribou Biosciences, Inc. has released promising updates on the ANTLER Phase 1 trial of their anti-CD19 CAR-T cell therapy, CB-010, for patients with relapsed or refractory B cell non-Hodgkin lymphoma. Engaging discussions with key opinion leaders and management were part of a webcast on the data, all of which is accessible through the Company’s website. Investors and interested parties can look forward to a detailed presentation at the upcoming ASCO Annual Meeting.
See more insights into CRBU stock on TipRanks’ Stock Analysis page.